TipRanks
Biogen (BIIB)
NASDAQ:BIIB
US Market
BIIB
Biogen
RESEARCH TOOLSreports
Want to see BIIB full AI Analyst Report?

Biogen (BIIB) Stock Forecast & Price Target

5,071 Followers
See the Price Targets and Ratings of:

BIIB Analyst Ratings

Moderate Buy
26Ratings
Moderate Buy
18 Buy
7 Hold
1 Sell
Based on 26 analysts giving stock ratings to
Biogen
in the past 3 months
TipRanks enables you to focus on the analyst rating consensus of all analysts or only the top performers​ in the past 3 months

BIIB Stock 12 Month Forecast

Average Price Target

$242.29
▲(9.60% Upside)
Based on 26 Wall Street analysts offering 12 month price targets for Biogen in the last 3 months. The average price target is $242.29 with a high forecast of $300.00 and a low forecast of $175.00. The average price target represents a 9.60% change from the last price of $221.07.
{"navigator":{"disabled":true},"exporting":{"enabled":false},"title":{"text":null},"chart":{"height":200,"style":{"fontFamily":"Roboto Flex, -apple-system, BlinkMacSystemFont, Segoe UI, Roboto, Helvetica, Arial, sans-serif, Apple Color Emoji, Segoe UI Emoji, Segoe UI Symbol","fontWeight":"400","color":"#5d5d5e"},"spacingTop":30,"spacingRight":60,"events":null},"yAxis":{"labels":{"style":{"color":"inherit"},"distance":6,"x":-6,"y":-6,"zIndex":1,"map_label_formatter":{"153":"$153","190":"$190","227":"$227","264":"$264","301":"$301"}},"plotLines":[{"color":"rgba(0,0,0,0)","value":300,"label":{"className":" overflowvisible_force","align":"right","x":60,"y":-10,"text":"<div  class=\"positionrelative hoverZ3 triangleleft-bottom flexccc bgwhite shadowhard-3 border1 borderColorwhite-8 colorwhite-8 px2 lineHeight3 fontWeightsemibold fontSize10 radiismall h_pxsmall35\"> <div class=\"w_pxsmall60 flexccc\">\n  <span style=\"color:#199ca5\">High </span>\n\n  <span style=\"color:#199ca5\">$300.00</span>\n  </div></div>","useHTML":true}},{"color":"rgba(0,0,0,0)","value":242.29166666666663,"label":{"className":" overflowvisible_force","align":"right","x":60,"y":0,"text":"<div  class=\"positionrelative hoverZ3 triangleleft flexccc bgwhite shadowhard-3 border1 borderColorwhite-8 colorwhite-8 px2 lineHeight3 fontWeightsemibold fontSize10 radiismall h_pxsmall35\"> <div class=\"w_pxsmall60 flexccc\">\n  <span style=\"color:#828080\">Average </span>\n\n  <span style=\"color:#828080\">$242.29</span>\n  </div></div>","useHTML":true}},{"color":"rgba(0,0,0,0)","value":175,"label":{"className":" overflowvisible_force","align":"right","x":60,"y":10,"text":"<div  class=\"positionrelative hoverZ3 triangleleft-top flexccc bgwhite shadowhard-3 border1 borderColorwhite-8 colorwhite-8 px2 lineHeight3 fontWeightsemibold fontSize10 radiismall h_pxsmall35\"> <div class=\"w_pxsmall60 flexccc\">\n  <span style=\"color:#912767\">Low </span>\n\n  <span style=\"color:#912767\">$175.00</span>\n  </div></div>","useHTML":true}}],"tickPositions":[153,190,227,264,301],"lineColor":"#dddddd","gridLineWidth":1,"gridLineColor":"#dddddd","lineWidth":1,"title":{"text":""}},"plotOptions":{"series":{"states":{"inactive":{"opacity":1}}},"line":{"animation":{"duration":0},"dataLabels":{"allowOverlap":true},"borderWidth":1,"marker":{"enabled":true,"fillColor":"#FFFFFF","radius":3,"lineWidth":2,"symbol":"circle","lineColor":"#828080"}}},"xAxis":{"labels":{"style":{"color":"inherit"},"rotation":0,"map_label_formatter":{"3":"Jan<br/>2026","6":"Apr<br/>2026","9":"Jul<br/>2026","12":"Oct<br/>2026","25":"Oct<br/>2027"}},"tickPositions":[3,6,9,12,25],"plotLines":[{"color":"#dddddd","width":1,"value":12},{"color":"#dddddd","width":1,"value":12}],"lineWidth":0,"gridLineWidth":1,"gridLineColor":"#dddddd","tickLength":0},"legend":{"symbolRadius":0,"symbolPadding":4,"symbolHeight":14,"borderWidth":0,"symbolWidth":14,"align":"left","verticalAlign":"bottom","enabled":false},"tooltip":{"backgroundColor":"rgba(0,0,0,0)","useHTML":true,"borderWidth":0,"borderColor":"rgba(0,0,0,0)","padding":0,"shadow":null,"headerFormat":"","footerFormat":"","pointFormat":"<div class=\"flexccc lineHeight2 bgwhite shadow2 px3 py3 radiismall fonth10_semibold\">\n                <span class=\"colorgray-3 mb4\">{point.date:%b %d ,%Y}</span>\n                <span>Analyst Consensus</span>\n                {point.info}\n          </div>\n           </div>"},"credits":{"enabled":false},"accessibility":{"description":""},"responsive":{"rules":[{"chartOptions":{"chart":{"spacing":[0,0,0,0],"margin":[30,60,40,5]},"xAxis":{"tickPositions":[3,12,25.25]},"yAxis":{"labels":{"enabled":false}},"title":{"text":null},"subtitle":{"text":null}},"condition":{"maxWidth":500}}]},"series":[{"lineWidth":2,"dashStyle":"ShortDash","name":"High","type":"line","color":"#199ca5","enableMouseTracking":false,"marker":{"enabled":false},"data":[null,null,null,null,null,null,null,null,null,null,null,null,222.82,228.75692307692307,234.69384615384615,240.63076923076923,246.5676923076923,252.5046153846154,258.44153846153847,264.3784615384615,270.31538461538463,276.2523076923077,282.1892307692308,288.12615384615384,294.0630769230769,{"y":300,"marker":{"fillColor":"#199ca5","lineColor":"#199ca5","enabled":true,"symbol":"circle"}}]},{"lineWidth":2,"dashStyle":"ShortDash","name":"Average","type":"line","color":"#828080","enableMouseTracking":false,"marker":{"enabled":false},"data":[null,null,null,null,null,null,null,null,null,null,null,null,222.82,224.3178205128205,225.815641025641,227.31346153846152,228.81128205128203,230.30910256410255,231.80692307692306,233.30474358974357,234.80256410256408,236.3003846153846,237.7982051282051,239.2960256410256,240.79384615384612,{"y":242.29166666666663,"marker":{"fillColor":"#828080","lineColor":"#828080","enabled":true,"symbol":"circle"}}]},{"lineWidth":2,"dashStyle":"ShortDash","name":"Low","type":"line","color":"#912767","enableMouseTracking":false,"marker":{"enabled":false},"data":[null,null,null,null,null,null,null,null,null,null,null,null,222.82,219.14153846153846,215.46307692307693,211.7846153846154,208.10615384615383,204.4276923076923,200.74923076923076,197.07076923076923,193.3923076923077,189.71384615384613,186.0353846153846,182.35692307692307,178.67846153846153,{"y":175,"marker":{"fillColor":"#912767","lineColor":"#912767","enabled":true,"symbol":"circle"}}]},{"type":"line","data":[{"y":154.22,"date":1759276800000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 27,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 31, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":154.27,"date":1761955200000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 24,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 28, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":177.78,"date":1764547200000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 22,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 21, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 2</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":175.99,"date":1767225600000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 18,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 21, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 2</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":179.09,"date":1769904000000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 24,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 31, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 2</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":188.05,"date":1772323200000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 22,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 38, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 1</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":183.78,"date":1775001600000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 31,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 40, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 1</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":187.06,"date":1777593600000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 39,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 39, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 1</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":192.23,"date":1780272000000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 41,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 32, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":209.74,"date":1782864000000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 54,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 34, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 1</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":202.95,"date":1785542400000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 40,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 23, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 1</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":216.04,"date":1788220800000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 36,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 22, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 2</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":222.82,"date":1790812800000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 16,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 6, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 1</span>\n      ","marker":{"fillColor":"black","lineColor":"black","enabled":true,"symbol":"circle"}},null,null,null,null,null,null,null,null,null,null,null,null],"color":"#0666a7"}]}
Highest Price Target$300.00Average Price Target$242.29Lowest Price Target$175.00
The highest, average, and lowest price target of all analysts. Click on ‘Top Analysts’ to focus on the best performers.

Detailed List of Analyst Forecasts​

Detailed List of Analyst Forecasts​
Analyst Profile
Expert Firm
Price Target
Position
Upside / Downside
Action
Date
Follow
Article
Piper Sandler Analyst forecast on BIIB
David Amsellem
Piper Sandler
Piper Sandler
$245
Buy
10.82%
Upside
Reiterated
10/12/26
Piper Sandler Keeps Their Buy Rating on Biogen (BIIB)
Citi Analyst forecast on BIIB
Geoff Meacham
Citi
Citi
$215
Hold
-2.75%
Downside
Reiterated
10/12/26
Citi Remains a Hold on Biogen (BIIB)
BMO Capital Analyst forecast on BIIB
Evan Seigerman
BMO Capital
BMO Capital
$208→$220
Hold
-0.48%
Downside
Reiterated
10/12/26
Biogen price target raised to $220 from $208 at BMO CapitalBiogen price target raised to $220 from $208 at BMO Capital
J.P. Morgan Analyst forecast on BIIB
Chris Schott
J.P. Morgan
J.P. Morgan
$210→$300
Buy
35.70%
Upside
Upgraded
10/12/26
Biogen upgraded to Overweight from Neutral at JPMorganBiogen upgraded to Overweight from Neutral at JPMorgan
UBS Analyst forecast on BIIB
Michael Yee
UBS
UBS
$240→$270
Buy
22.13%
Upside
Assigned
10/09/26
Biogen price target raised to $270 from $240 at UBSBiogen price target raised to $270 from $240 at UBS
RBC Capital Analyst forecast on BIIB
Brian Abrahams
RBC Capital
RBC Capital
$260→$256
Buy
15.80%
Upside
Reiterated
10/08/26
Biogen price target lowered to $256 from $260 at RBC CapitalBiogen price target lowered to $256 from $260 at RBC Capital
Needham Analyst forecast on BIIB
Ami Fadia
Needham
Needham
$256
Buy
15.80%
Upside
Reiterated
10/06/26
Biogen Maintained at Buy as Analyst Sees Favorable Risk-Reward Ahead of Lupus Data; $256 Price Target Reaffirmed
Jefferies Analyst forecast on BIIB
Andrew Tsai
Jefferies
Jefferies
$255
Buy
15.35%
Upside
Reiterated
10/05/26
Analysts Are Bullish on Top Healthcare Stocks: Liquidia Technologies (LQDA), Kodiak Sciences (KOD)
Bernstein Analyst forecast on BIIB
Eve Burstein
Bernstein
Bernstein
$236
Buy
6.75%
Upside
Reiterated
09/25/26
Analysts Conflicted on These Healthcare Names: Harmony Biosciences Holdings (NASDAQ: HRMY), BioNTech SE (NASDAQ: BNTX) and Biogen (NASDAQ: BIIB)
Wells Fargo Analyst forecast on BIIB
Mohit Bansal
Wells Fargo
Wells Fargo
$250
Buy
13.09%
Upside
Reiterated
09/18/26
Analysts Offer Insights on Healthcare Companies: Neuronetics (NASDAQ: STIM), Xenon (NASDAQ: XENE) and Biogen (NASDAQ: BIIB)
HSBC Analyst forecast on BIIB
Morten Herholdt
HSBC
HSBC
$165→$175
Sell
-20.84%
Downside
Reiterated
09/10/26
Biogen price target raised to $175 from $165 at HSBCBiogen price target raised to $175 from $165 at HSBC
Wolfe Research Analyst forecast on BIIB
Alexandria Hammond
Wolfe Research
Wolfe Research
$300
Buy
35.70%
Upside
Upgraded
08/13/26
Analysts Offer Insights on Healthcare Companies: Apogee Therapeutics (NASDAQ: APGE) and Biogen (NASDAQ: BIIB)
Barclays Analyst forecast on BIIB
Emily Field
Barclays
Barclays
$200
Hold
-9.53%
Downside
Reiterated
08/12/26
Barclays Keeps Their Hold Rating on Biogen (BIIB)
Mizuho Securities Analyst forecast on BIIB
Salim Syed
Mizuho Securities
Mizuho Securities
$221→$241
Buy
9.02%
Upside
Reiterated
08/03/26
Mizuho Securities Keeps Their Buy Rating on Biogen (BIIB)
Stifel Nicolaus Analyst forecast on BIIB
Paul Matteis
Stifel Nicolaus
Stifel Nicolaus
$214→$242
Buy
9.47%
Upside
Reiterated
08/02/26
Stifel Nicolaus Remains a Buy on Biogen (BIIB)
Analyst Type
Any
Any
Human Analysts
Ranks
Any
Any
Analyst Rating
Any
Any
Upside/ Downside
Any
Any
Action
Any
Any
Analyst Profile
Expert Firm
Price Target
Position
Upside / Downside
Action
Date
Follow
Article
Piper Sandler Analyst forecast on BIIB
David Amsellem
Piper Sandler
Piper Sandler
$245
Buy
10.82%
Upside
Reiterated
10/12/26
Piper Sandler Keeps Their Buy Rating on Biogen (BIIB)
Citi Analyst forecast on BIIB
Geoff Meacham
Citi
Citi
$215
Hold
-2.75%
Downside
Reiterated
10/12/26
Citi Remains a Hold on Biogen (BIIB)
BMO Capital Analyst forecast on BIIB
Evan Seigerman
BMO Capital
BMO Capital
$208→$220
Hold
-0.48%
Downside
Reiterated
10/12/26
Biogen price target raised to $220 from $208 at BMO CapitalBiogen price target raised to $220 from $208 at BMO Capital
J.P. Morgan Analyst forecast on BIIB
Chris Schott
J.P. Morgan
J.P. Morgan
$210→$300
Buy
35.70%
Upside
Upgraded
10/12/26
Biogen upgraded to Overweight from Neutral at JPMorganBiogen upgraded to Overweight from Neutral at JPMorgan
UBS Analyst forecast on BIIB
Michael Yee
UBS
UBS
$240→$270
Buy
22.13%
Upside
Assigned
10/09/26
Biogen price target raised to $270 from $240 at UBSBiogen price target raised to $270 from $240 at UBS
RBC Capital Analyst forecast on BIIB
Brian Abrahams
RBC Capital
RBC Capital
$260→$256
Buy
15.80%
Upside
Reiterated
10/08/26
Biogen price target lowered to $256 from $260 at RBC CapitalBiogen price target lowered to $256 from $260 at RBC Capital
Needham Analyst forecast on BIIB
Ami Fadia
Needham
Needham
$256
Buy
15.80%
Upside
Reiterated
10/06/26
Biogen Maintained at Buy as Analyst Sees Favorable Risk-Reward Ahead of Lupus Data; $256 Price Target Reaffirmed
Jefferies Analyst forecast on BIIB
Andrew Tsai
Jefferies
Jefferies
$255
Buy
15.35%
Upside
Reiterated
10/05/26
Analysts Are Bullish on Top Healthcare Stocks: Liquidia Technologies (LQDA), Kodiak Sciences (KOD)
Bernstein Analyst forecast on BIIB
Eve Burstein
Bernstein
Bernstein
$236
Buy
6.75%
Upside
Reiterated
09/25/26
Analysts Conflicted on These Healthcare Names: Harmony Biosciences Holdings (NASDAQ: HRMY), BioNTech SE (NASDAQ: BNTX) and Biogen (NASDAQ: BIIB)
Wells Fargo Analyst forecast on BIIB
Mohit Bansal
Wells Fargo
Wells Fargo
$250
Buy
13.09%
Upside
Reiterated
09/18/26
Analysts Offer Insights on Healthcare Companies: Neuronetics (NASDAQ: STIM), Xenon (NASDAQ: XENE) and Biogen (NASDAQ: BIIB)
HSBC Analyst forecast on BIIB
Morten Herholdt
HSBC
HSBC
$165→$175
Sell
-20.84%
Downside
Reiterated
09/10/26
Biogen price target raised to $175 from $165 at HSBCBiogen price target raised to $175 from $165 at HSBC
Wolfe Research Analyst forecast on BIIB
Alexandria Hammond
Wolfe Research
Wolfe Research
$300
Buy
35.70%
Upside
Upgraded
08/13/26
Analysts Offer Insights on Healthcare Companies: Apogee Therapeutics (NASDAQ: APGE) and Biogen (NASDAQ: BIIB)
Barclays Analyst forecast on BIIB
Emily Field
Barclays
Barclays
$200
Hold
-9.53%
Downside
Reiterated
08/12/26
Barclays Keeps Their Hold Rating on Biogen (BIIB)
Mizuho Securities Analyst forecast on BIIB
Salim Syed
Mizuho Securities
Mizuho Securities
$221→$241
Buy
9.02%
Upside
Reiterated
08/03/26
Mizuho Securities Keeps Their Buy Rating on Biogen (BIIB)
Stifel Nicolaus Analyst forecast on BIIB
Paul Matteis
Stifel Nicolaus
Stifel Nicolaus
$214→$242
Buy
9.47%
Upside
Reiterated
08/02/26
Stifel Nicolaus Remains a Buy on Biogen (BIIB)
Stocks with the Highest Top Analyst Consensus in the Healthcare Sector
ONCBeOne Medicines
OVIDOvid Therapeutics
ASNDAscendis Pharma
QNCXQuince Therapeutics
EHCEncompass Health
Find stocks in the Healthcare sector that are highly recommended by Top Performing Analysts.

Best Analysts Covering Biogen

3 Months
Salveen RichterGoldman Sachs
Success Rate
16/27 ratings generated profit
59%
Average Return
+2.02%
Copying Salveen Richter's trades and holding each position for 3 Months would result in 59.26% of your transactions generating a profit, with an average return of +2.02% per trade.
1 Year
Myles MinterWilliam Blair
Success Rate
16/23 ratings generated profit
70%
Average Return
+18.10%
Copying Myles Minter's trades and holding each position for 1 Year would result in 69.57% of your transactions generating a profit, with an average return of +18.10% per trade.
2 Years
Myles MinterWilliam Blair
Success Rate
15/23 ratings generated profit
65%
Average Return
+16.36%
Copying Myles Minter's trades and holding each position for 2 Years would result in 65.22% of your transactions generating a profit, with an average return of +16.36% per trade.
The Best Analyst Covering tool allows you to follow the analysts who have the best success rates and average returns on a specific stock. Only analysts that gave a Buy or Sell rating on the stock in the past 12 months are eligible for inclusion in this tool. Follow the analysts of your choice to receive real-time updates when they publish a new rating.

BIIB Analyst Recommendation Trends

Rating
Jun 26
Jul 26
Aug 26
Sep 26
Oct 26
Strong Buy
0
0
0
0
0
Buy
41
54
40
36
16
Hold
32
34
23
22
6
Sell
0
1
1
2
1
Strong Sell
0
0
0
0
0
total
73
89
64
60
23
In the current month, BIIB has received 16 Buy Ratings, 6 Hold Ratings, and 1 Sell Ratings. BIIB average Analyst price target in the past 3 months is 242.29.
Each month's total comprises the sum of three months' worth of ratings.

BIIB Financial Forecast

BIIB Earnings Forecast

Next quarter’s earnings estimate for BIIB is $2.00 with a range of $1.44 to $2.67. The previous quarter’s EPS was $3.60. BIIB beat its EPS estimate ― of the time in the past 12 months, while its overall industry beat the EPS estimate 57.80% of the time in the same period. In the last calendar year BIIB has Performed in-line its overall industry.
Next quarter’s earnings estimate for BIIB is $2.00 with a range of $1.44 to $2.67. The previous quarter’s EPS was $3.60. BIIB beat its EPS estimate ― of the time in the past 12 months, while its overall industry beat the EPS estimate 57.80% of the time in the same period. In the last calendar year BIIB has Performed in-line its overall industry.

BIIB Sales Forecast

Next quarter’s sales forecast for BIIB is $2.64B with a range of $2.50B to $2.73B. The previous quarter’s sales results were $2.62B. BIIB beat its sales estimates ― of the time in past 12 months, while its overall industry beat sales estimates 50.04% of the time in the same period. In the last calendar year BIIB has Performed in-line its overall industry.
Next quarter’s sales forecast for BIIB is $2.64B with a range of $2.50B to $2.73B. The previous quarter’s sales results were $2.62B. BIIB beat its sales estimates ― of the time in past 12 months, while its overall industry beat sales estimates 50.04% of the time in the same period. In the last calendar year BIIB has Performed in-line its overall industry.

BIIB Stock Forecast FAQ

What is BIIB’s average 12-month price target, according to analysts?
Based on analyst ratings, Biogen’s 12-month average price target is 242.29.
    What is BIIB’s upside potential, based on the analysts’ average price target?
    Biogen has 9.60% upside potential, based on the analysts’ average price target.
      Can I see which stocks the top-ranking analysts are rating?
      Yes, go to the Analysts’ Top Stocks tool to see stocks with a Strong Buy or Strong Sell analyst rating consensus, according to the top performers.
        How can I follow the stock ratings of top Wall Street analysts?
        Head over to our Expert Center to see a list of the top 100 Wall Street analysts and follow the analysts of your choice. Visit their profiles for more details about their stock ratings and see how they perform on a stock-by-stock basis.
          Is BIIB a Buy, Sell or Hold?
          Biogen has a consensus rating of Moderate Buy which is based on 18 buy ratings, 7 hold ratings and 1 sell ratings.
            What is Biogen’s price target?
            The average price target for Biogen is 242.29. This is based on 26 Wall Streets Analysts 12-month price targets, issued in the past 3 months.
            The highest analyst price target is $300.00 ,the lowest forecast is $175.00. The average price target represents 9.60% Increase from the current price of $221.07.
              What do analysts say about Biogen?
              Biogen’s analyst rating consensus is a Moderate Buy. This is based on the ratings of 26 Wall Streets Analysts.
                How can I buy shares of BIIB?
                Open a brokerage account, see exclusive account opening deals on our Best Online Brokers page.